Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Buspar (US brand discontinued; generic widely available) (1)

Analgesic (2) · GABAergic (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Anxiolytics|Anxiolytic]] (1) · [[:Category:Azapirones|Azapirone]] (1) · [[:Category:Serotonin 5-HT1A partial agonists|Serotonin 5-HT1A partial agonist]] (1)

None (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug of GHB (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1)

None (2) · 5 mg PO TID or 7.5 mg PO BID; titrate by 5 mg every 2-3 days to clinical effect, commonly 30-60 mg/day divided BID-TID (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 5, 7.5, 10, 15, 30 mg (the 15 and 30 mg tablets are scored for halving and quartering) (1)

None (2) · 360 mg/day (1) · 60 mg/day (1)

None (2) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · '''Anxiolytic effect emerges over 2-4 weeks'''; buspirone does NOT work for acute anxiety, which is the central teaching point and the most common cause of treatment failure (1) · 30–60 min (PO) (1)

None (2) · 4–6 hours (1) · ~8 hours (TID dosing) (1)

None (2) · 2.5–3 hours (1) · Buspirone 2-3 hours; 1-PP active metabolite 4-6 hours'"`UNIQ--ref-0000001D-QINU`"' (1)

None (2) · ~4% (extensive first-pass metabolism)'"`UNIQ--ref-0000001E-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data; older agent with substantial use experience and no clear teratogenic signal.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over benzodiazepine alternatives for chronic anxiety'"`UNIQ--ref-0000001F-QINU`"' (1)